If additional clinical results are available for Public information then the presenting Pharma will show an updated slide. Following from that would be a PR, news event, update for Shareholders. ONCS is looking for financial partner(s) especially to launch their EMA approved OMS ElectroImmunotherapy Neopulse bleomycin technology throughout Europe. ONCS EMA approved technology at 14,000 volts and localized Bleomycin is significantly different and potentially less chemo destructive than the EMA approved Italian IGEA 1000 volt Bleomycin intravenous technology.